Company Overview
Codexis, Inc. operates within the healthcare sector specifically as a biotechnology company, providing technology solutions focused on therapeutics manufacturing. The firm leverages its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes across a global footprint that includes the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, and New Zealand. This operational scope is supported by a workforce of 146 employees who facilitate the company's research and development activities. With a market capitalization of $159.02M and annual revenue of $70.39M, the company maintains a mid-cap profile that suggests it is an established player yet retains significant room for expansion within the specialized enzyme market. These valuation metrics indicate that the market values Codexis at a premium relative to its current sales base, reflecting high expectations for future commercialization of its technology solutions in the biotechnology industry.
Financial Health
The company reported revenue of $70.39M over the trailing twelve months, while net income stood at -$43,974,000 and EBITDA was -$33,084,000, highlighting a significant disparity between top-line growth and profitability. The gap between revenue and net income reveals a heavy cost structure where operating expenses, likely driven by R&D and platform development, consume the majority of generated income before taxes and interest. Free cash flow for the period was -$5,074,125, indicating that the company is currently burning cash to fund its operations and growth initiatives rather than generating liquidity from core business activities. This negative cash flow position suggests limited financial flexibility in the short term, requiring the firm to rely on existing cash reserves or external financing to sustain operations. The gross margin is 12.4%, which indicates low profitability on the cost of goods sold typical for biomanufacturing startups, while the operating margin of 35.9% demonstrates efficient management of operating expenses relative to revenue. However, the profit margin of -62.5% confirms that the company is not yet profitable on a bottom-line basis. On the balance sheet, the company holds $78.21M in cash against $73.21M in debt, resulting in a debt-to-equity ratio of 144.88, which signifies a highly leveraged capital structure where debt exceeds equity. Despite the high leverage, the current ratio of 3.82 indicates strong short-term liquidity, as the company possesses more than three times the current assets needed to cover its current liabilities. Return on Equity is -74.9% and Return on Assets is -16.1%, metrics that reveal management is currently unable to generate positive returns on the capital invested or assets held due to the persistent net losses.
Valuation Assessment
The trailing P/E ratio is N/A due to the lack of positive earnings, whereas the forward P/E is -4.61, a figure that implies the market is pricing in future earnings recovery rather than current performance. The price-to-book ratio stands at 3.14, indicating that the market values the company at more than three times its book value, which suggests a significant premium placed on its intangible assets and technology platform. The price-to-sales ratio is 2.26, and the EV/EBITDA is -4.66, suggesting that valuation is being driven primarily by revenue multiples and cash position rather than traditional earnings-based metrics. The stock has traded between a 52-week high of $3.87 and a 52-week low of $0.96, with the current price trading significantly below the recent highs, reflecting the market's cautious stance on the company's near-term earnings trajectory. The beta value is 2.50, which means the stock is expected to be 150% more volatile than the broader market, exposing investors to substantial price swings in response to market movements or sector-specific developments.
Growth & Income
Revenue growth over the last year was 81.3%, while earnings growth is N/A because the company has not yet achieved consistent profitability, implying that top-line expansion is outpacing the ability to turn operations into net income. As a non-dividend payer, the company maintains a dividend yield of N/A and a payout ratio of 0.0%, which indicates that all available earnings are retained within the company to fund research, development, and operational scaling rather than being distributed to shareholders. This reinvestment strategy is typical for biotechnology firms in the growth phase that prioritize expanding their enzyme portfolio over returning capital to investors. The overall growth and income profile is characterized by rapid revenue expansion supported by strong liquidity but constrained by a lack of current earnings and a high degree of financial leverage.